Crossmark

Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

Crossref DOI link: https://doi.org/10.1038/s41409-020-01182-w

Published Online: 2021-01-15

Published Print: 2021-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pettengell, R. https://orcid.org/0000-0001-9948-660X
Uddin, R.

Boumendil, A.

Johnson, R.

Metzner, B.

Martín, A.

Romejko-Jarosinska, J.

Bence-Bruckler, I.

Giri, P.

Niemann, C. U.

Robinson, S. P.

Kimby, E.

Schmitz, N.

Dreger, P. https://orcid.org/0000-0002-7429-8570
Goldstone, A. H.

Montoto, S.
License Information

Text and Data Mining valid from 2021-01-15

Version of Record valid from 2021-01-15
More Information

Article History

Received: 3 April 2020

Revised: 12 October 2020

Accepted: 30 November 2020

First Online: 15 January 2021

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below